Alexion Pharmaceuticals Announces Presentation of Soliris Data at ASH

Alexion Pharmaceuticals Announces Presentation of Soliris Data at ASH

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that
researchers presented data from clinical trials demonstrating the
clinical benefits of chronic Soliris® (eculizumab) treatment
in patients with atypical hemolytic uremic syndrome (aHUS) as well as
new patient registry data providing further insight into optimal care
for patients with paroxysmal nocturnal hemoglobinuria (PNH) at the
American Society of Hematology (ASH) 55th Annual Meeting and Exposition
in New Orleans. Data included:

A new, comprehensive study of key aHUS biomarkers indicating that,
prior to initiation of Soliris treatment, aHUS patients have severe
ongoing terminal complement activation and inflammation with increased
thrombotic risk. The study further indicates

See full press release

Posted-In: News Guidance Management Global


Benzinga – Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals


Uncategorized

Leave a Reply

Your email address will not be published. Required fields are marked *